867 related articles for article (PubMed ID: 27774908)
1. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
[TBL] [Abstract][Full Text] [Related]
3. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of gene expression as an anticancer drug target.
Ferguson LR; Tatham AL; Lin Z; Denny WA
Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
9. Small-molecular modulators of cancer-associated epigenetic mechanisms.
Itoh Y; Suzuki T; Miyata N
Mol Biosyst; 2013 May; 9(5):873-96. PubMed ID: 23511667
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics in cancer: targeting chromatin modifications.
Ellis L; Atadja PW; Johnstone RW
Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Modification in Macrophages: A Promising Target for Tumor and Inflammation-associated Disease Therapy.
Sun P; Zhang SJ; Maksim S; Yao YF; Liu HM; Du J
Curr Top Med Chem; 2019; 19(15):1350-1362. PubMed ID: 31215380
[TBL] [Abstract][Full Text] [Related]
12. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
13. Promises and challenges of anticancer drugs that target the epigenome.
Verbrugge I; Johnstone RW; Bots M
Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
[TBL] [Abstract][Full Text] [Related]
14. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic transitions: towards therapeutic targets.
Kalebic T
Expert Opin Ther Targets; 2003 Dec; 7(6):693-9. PubMed ID: 14640906
[TBL] [Abstract][Full Text] [Related]
16. DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.
Castillo-Aguilera O; Depreux P; Halby L; Arimondo PB; Goossens L
Biomolecules; 2017 Jan; 7(1):. PubMed ID: 28067760
[TBL] [Abstract][Full Text] [Related]
17. Review-Epigenetic therapy for cancer.
Saleem M; Abbas K; Manan M; Ijaz H; Ahmed B; Ali M; Hanif M; Farooqi AA; Qadir MI
Pak J Pharm Sci; 2015 May; 28(3):1023-32. PubMed ID: 26004710
[TBL] [Abstract][Full Text] [Related]
18. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
Perez-Plasencia C; Duenas-Gonzalez A
Mol Cancer; 2006 Jul; 5():27. PubMed ID: 16831224
[TBL] [Abstract][Full Text] [Related]
19. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
20. Histone modification therapy of cancer.
Biancotto C; Frigè G; Minucci S
Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]